MarketCapExport financials
Celldex Therapeutics (CLDX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Celldex Therapeutics Balance Sheet 2025-2008 | CLDX
Brief overview of Celldex Therapeutics's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
The balance sheet expanded from $444.7 million to $583 million. Growth of +31.1% and CAGR of 7% look measured and sustainable.
Liabilities expanded faster than the asset base, +121.7% versus +31.1%. Debt-service capacity deserves attention.
The equity-to-assets ratio is 90.4%, compared with 94.3% five periods ago. The balance sheet has a substantial internal cushion.
Net debt moved below zero to -$26.5 million, reflecting surplus cash over debt.
The cash share moved from 8.8% to 5%. A higher figure generally provides more room in an adverse scenario.
The accumulated result is -$1.8 billion and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Conclusion
Celldex Therapeutics's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-26.5 M | -24.5 M | -32.3 M | -25.4 M | -36.1 M | - | -7.58 M | -19.8 M | -33.7 M | -42.5 M | -67.7 M | -25.4 M | -169 M | -13.6 M | 3.46 M | - | - | - |
Long Term Debt |
784 K | 2.36 M | 928 K | 2.59 M | 1.3 M | - | - | - | - | - | - | - | - | 5.75 M | 9.01 M | - | - | - |
Long Term Debt Current |
1.55 M | 1.45 M | 1.61 M | 1.44 M | 1.75 M | 1.33 M | 1.94 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 17.3 M | 19.1 M | 51.5 M | 82.7 M | 17.2 M | 11.9 M | 6.95 M | 12.1 M | 15 M | - | - | - |
Total Current Liabilities |
51 M | 39.5 M | 31.1 M | 18.6 M | 16.5 M | 14.2 M | 11.6 M | 12.6 M | 27.7 M | 35.2 M | 30.2 M | 24.5 M | 20.4 M | 17.7 M | 14.3 M | 20.2 M | - | - |
Total Liabilities |
55.8 M | 45.3 M | 36.5 M | 26.5 M | 25.2 M | 26.5 M | 28.9 M | 31.7 M | 79.3 M | 118 M | 47.5 M | 36.4 M | 27.3 M | 29.8 M | 29.3 M | 34.7 M | - | - |
Retained Earnings |
-1.81 B | -1.56 B | -1.4 B | -1.26 B | -1.14 B | -1.07 B | -1.01 B | -962 M | -813 M | -719 M | -591 M | -464 M | -346 M | -264 M | -205 M | -160 M | - | - |
Total Assets |
583 M | 792 M | 466 M | 353 M | 445 M | 236 M | 123 M | 156 M | 316 M | 383 M | 338 M | 248 M | 347 M | 126 M | 98 M | 110 M | - | - |
Cash and Cash Equivalents |
28.9 M | 28.4 M | 34.8 M | 29.4 M | 39.1 M | 43.8 M | 11.2 M | 24.3 M | 40.3 M | 42.5 M | 72.1 M | 28 M | 169 M | 24.9 M | 11.9 M | 21.3 M | 57 M | 44.3 M |
Book Value |
527 M | 747 M | 429 M | 326 M | 419 M | 209 M | 94 M | 124 M | 236 M | 265 M | 290 M | 212 M | 320 M | 95.8 M | 68.7 M | 75.3 M | - | - |
Total Shareholders Equity |
527 M | 747 M | 429 M | 326 M | 419 M | 209 M | 94 M | 124 M | 236 M | 265 M | 290 M | 212 M | 320 M | 95.8 M | 68.7 M | 75.3 M | 73.8 M | 18.1 M |
All numbers in USD currency
Quarterly Balance Sheet Celldex Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.35 M | 443 K | 1.07 M | 1.5 M | 1.93 M | 2.36 M | 1.71 M | 796 K | 470 K | 928 K | 1.3 M | 1.72 M | 2.16 M | 2.59 M | 2.19 M | 2.59 M | 841 K | 1.3 M | 1.71 M | 1.45 M | 1.76 M | 2.15 M | 2.15 M | 2.15 M | 2.15 M | 1.71 M | 1.71 M | 1.71 M | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
67.8 M | 55 M | 50.1 M | 37 M | 36.5 M | 45.3 M | 37.3 M | 31.9 M | 30.2 M | 36.5 M | 33.5 M | 21.8 M | 21.8 M | 26.5 M | 23.8 M | 37.9 M | 25.9 M | 25.2 M | 23.5 M | 22.3 M | 24.9 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 28.9 M | 28.9 M | 28.9 M | 28.9 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 79.3 M | 79.3 M | 79.3 M | 79.3 M | 118 M | 118 M | 118 M | 118 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 36.4 M | 36.4 M | 36.4 M | 36.4 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M |
Retained Earnings |
-1.97 B | -1.89 B | -1.73 B | -1.67 B | -1.61 B | -1.56 B | -1.51 B | -1.47 B | -1.43 B | -1.4 B | -1.35 B | -1.32 B | -1.29 B | -1.26 B | -1.23 B | -1.2 B | -1.17 B | -1.14 B | -1.12 B | -1.1 B | -1.09 B | -1.07 B | -1.07 B | -1.07 B | -1.07 B | -1.01 B | -1.01 B | -1.01 B | -1.01 B | -962 M | -962 M | -962 M | -962 M | -813 M | -813 M | -813 M | -813 M | -719 M | -719 M | -719 M | -719 M | -591 M | -591 M | -591 M | -591 M | -464 M | -464 M | -464 M | -464 M | -346 M | -346 M | -346 M | -346 M | -264 M | -264 M | -264 M | -264 M | -205 M | -205 M | -205 M | -205 M |
Total Assets |
782 M | 511 M | 648 M | 692 M | 739 M | 792 M | 823 M | 846 M | 869 M | 466 M | 280 M | 299 M | 325 M | 353 M | 369 M | 403 M | 424 M | 445 M | 460 M | 205 M | 219 M | 236 M | 236 M | 236 M | 236 M | 123 M | 123 M | 123 M | 123 M | 156 M | 156 M | 156 M | 156 M | 316 M | 316 M | 316 M | 316 M | 383 M | 383 M | 383 M | 383 M | 338 M | 338 M | 338 M | 338 M | 248 M | 248 M | 248 M | 248 M | 347 M | 347 M | 347 M | 347 M | 126 M | 126 M | 126 M | 126 M | 98 M | 98 M | 98 M | 98 M |
Cash and Cash Equivalents |
47.5 M | 35.7 M | 36 M | 23 M | 17.1 M | 28.4 M | 36.4 M | 42.7 M | 115 M | 34.8 M | 21.1 M | 28.2 M | 54.1 M | 29.4 M | 18.6 M | 28.4 M | 25.3 M | 39.1 M | 72.2 M | 43.4 M | 69.3 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 24.3 M | 24.3 M | 24.3 M | 24.3 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 72.1 M | 72.1 M | 72.1 M | 72.1 M | 28 M | 28 M | 28 M | 28 M | 169 M | 169 M | 169 M | 169 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M |
Book Value |
715 M | 456 M | 598 M | 655 M | 703 M | 747 M | 786 M | 814 M | 839 M | 429 M | 247 M | 278 M | 303 M | 326 M | 345 M | 365 M | 398 M | 419 M | 437 M | 182 M | 194 M | 209 M | 209 M | 209 M | 209 M | 94 M | 94 M | 94 M | 94 M | 124 M | 124 M | 124 M | 124 M | 236 M | 236 M | 236 M | 236 M | 265 M | 265 M | 265 M | 265 M | 290 M | 290 M | 290 M | 290 M | 212 M | 212 M | 212 M | 212 M | 320 M | 320 M | 320 M | 320 M | 95.8 M | 95.8 M | 95.8 M | 95.8 M | 68.7 M | 68.7 M | 68.7 M | 68.7 M |
Total Shareholders Equity |
715 M | 456 M | 598 M | 655 M | 703 M | 747 M | 786 M | 814 M | 839 M | 429 M | 247 M | 278 M | 303 M | 326 M | 345 M | 365 M | 398 M | 419 M | 437 M | 182 M | 194 M | 209 M | 209 M | 209 M | 209 M | 94 M | 94 M | 94 M | 94 M | 124 M | 124 M | 124 M | 124 M | 236 M | 236 M | 236 M | 236 M | 265 M | 265 M | 265 M | 265 M | 290 M | 290 M | 290 M | 290 M | 212 M | 212 M | 212 M | 212 M | 320 M | 320 M | 320 M | 320 M | 95.8 M | 95.8 M | 95.8 M | 95.8 M | 68.7 M | 68.7 M | 68.7 M | 68.7 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Celldex Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Schweiz
USA
Israel
China
Canada
Britain
Russia
